{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:31:52Z","timestamp":1782768712691,"version":"3.54.5"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.resinv.2025.101337","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:07:14Z","timestamp":1764119234000},"page":"101337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["How to choose a biologic agent considering comorbidities of bronchial asthma"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-5245","authenticated-orcid":false,"given":"Masamichi","family":"Itoga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-4143","authenticated-orcid":false,"given":"Sadatomo","family":"Tasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.101337_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12219","article-title":"The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis","volume":"13","author":"Spekhorst","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.resinv.2025.101337_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2147\/JAA.S391896","article-title":"Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma irrespective of baseline asthma characteristics","volume":"16","author":"Busse","year":"2023","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.resinv.2025.101337_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12081304","article-title":"Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study","volume":"12","author":"Gallo","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.resinv.2025.101337_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00408-024-00717-y","article-title":"Efficacy of biologics in patients with allergic bronchopulmonary aspergillosis: a systematic review and meta-analysis","volume":"202","author":"Chen","year":"2024","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2025.101337_bib5","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0133-2023","article-title":"Management of comorbidities in difficult and severe asthma","volume":"19","author":"Khan","year":"2023","journal-title":"Breathe"},{"key":"10.1016\/j.resinv.2025.101337_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41533-024-00381-y","article-title":"Change is in the air: key questions on the 'Treatable Traits' model for chronic airway diseases in primary care","volume":"34","author":"Agusti","year":"2024","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.resinv.2025.101337_bib9","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/1346-8138.16119","article-title":"Predictive features associated with chronic spontaneous urticaria recurrence","volume":"48","author":"Toubi","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.resinv.2025.101337_bib11","first-page":"133","article-title":"Clinical and immunological features of bronchial asthma comorbid chronic urticaria: a retrospective Study","volume":"186","author":"Du","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib12","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamadermatol.2021.3237","article-title":"Evaluation of pharmacologic treatments for H1 antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","volume":"157","author":"Nochaiwong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.resinv.2025.101337_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaip.2021.10.022","article-title":"Impact of pharmacological treatments for chronic spontaneous urticaria with an inadequate response to H1-Antihistamines on health-related quality of life: a systematic review and network meta-analysis","volume":"10","author":"Nochaiwong","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib14","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2015.12.1342","article-title":"Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials","volume":"137","author":"Zhao","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and harms of omalizumab treatment in adolescent and adult patients with chronic idiopathic (Spontaneous) urticaria: a meta-analysis of \"Real-world\" evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.resinv.2025.101337_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fped.2019.00213","article-title":"Successful treatment with omalizumab in a child with asthma and urticaria: a clinical case report","volume":"7","author":"Sirufo","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.resinv.2025.101337_bib18","doi-asserted-by":"crossref","unstructured":"Hutyrova B, Bystron J, Chlumsky J, Kindlova D, Klosova J, Krcmova I, et al. Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma \u2013 real life experience from Czech Anti-IgE Registry. Eur Respir J;50:PA3541.","DOI":"10.1183\/1393003.congress-2017.PA3541"},{"key":"10.1016\/j.resinv.2025.101337_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaad.2020.02.055","article-title":"Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis","volume":"84","author":"Ravnborg","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.resinv.2025.101337_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. working Party's diagnostic Criteria for Atopic dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.resinv.2025.101337_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.resinv.2025.101337_bib23","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology european prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.resinv.2025.101337_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105164","article-title":"Prurigo nodularis: pathogenesis and the horizon of potential therapeutics","volume":"25","author":"Yook","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2025.101337_bib25","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2025.101337_bib26","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International consensus statement on allergy and rhinology: rhinosinusitis 2021","volume":"11","author":"Orlandi","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.resinv.2025.101337_bib27","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2012","volume":"23","author":"Fokkens","year":"2012","journal-title":"Rhinol Suppl"},{"key":"10.1016\/j.resinv.2025.101337_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2015.12.1324","article-title":"Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers","volume":"137","author":"Tomassen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib29","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1435\u201341","key":"10.1016\/j.resinv.2025.101337_bib30","article-title":"T-cell regulation in chronic paranasal sinus disease","volume":"121","author":"Van Bruaene","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/194589240401800307","article-title":"Histopathological features of nasal polyps with asthma association: an immunohistochemical study","volume":"18","author":"Haruna","year":"2004","journal-title":"Am J Rhinol"},{"key":"10.1016\/j.resinv.2025.101337_bib32","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.101337_bib34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib35","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.resinv.2025.101337_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2025.101337_bib37","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000370122","article-title":"Eosinophilic otitis media is associated with asthma severity and smoking history","volume":"77","author":"Seo","year":"2015","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"10.1016\/j.resinv.2025.101337_bib39","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.anl.2010.11.016","article-title":"Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease","volume":"38","author":"Iino","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.resinv.2025.101337_bib40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MAO.0000000000003850","article-title":"Improvement of suspected eosinophilic otitis media with targeted biologic therapy","volume":"44","author":"Ryder","year":"2023","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.resinv.2025.101337_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040926","article-title":"Efficacy of biologics on refractory eosinophilic otitis media associated with bronchial asthma or severe uncontrolled CRSwNP","volume":"11","author":"De Corso","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.resinv.2025.101337_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.anl.2020.09.001","article-title":"Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma","volume":"48","author":"Iino","year":"2021","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.resinv.2025.101337_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.anl.2018.07.011","article-title":"Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media","volume":"46","author":"Iino","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.resinv.2025.101337_bib44","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/lary.29730","article-title":"Complete remission of severe eosinophilic otitis media with dupilumab: a case report","volume":"131","author":"van der Lans","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.resinv.2025.101337_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international chapel hill Consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2025.101337_bib46","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1164\/rccm.202005-1628SO","article-title":"International Consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis","volume":"202","author":"Moiseev","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101337_bib47","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/art.21250","article-title":"Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome","volume":"52","author":"Sinico","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.resinv.2025.101337_bib48","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jaci.2012.05.058","article-title":"Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome","volume":"131","author":"Healy","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib49","first-page":"37","article-title":"[survey of asthma control and anti-asthma medication use among Japanese adult patients]","volume":"59","author":"Fukutomi","year":"2010","journal-title":"Arerugi"},{"key":"10.1016\/j.resinv.2025.101337_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","article-title":"Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome","volume":"63","author":"Lanham","year":"1984","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.resinv.2025.101337_bib51","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jaci.2025.03.006","article-title":"Clinical and mechanistic advancements in aspirin exacerbated respiratory disease","volume":"155","author":"Elahi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib52","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101337_bib53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib54","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaip.2025.03.033","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma and aspirin-exacerbated respiratory disease in NAVIGATOR","volume":"13","author":"Laidlaw","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib55","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s12325-024-02889-8","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma across multiple clinically relevant subgroups in the NAVIGATOR study","volume":"41","author":"Carr","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.101337_bib56","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision","volume":"140","author":"Brozek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2332\/allergolint.08-OA-0004","article-title":"Analysis of the comorbidity of bronchial asthma and allergic rhinitis by questionnaire in 10,009 patients","volume":"58","author":"Yamauchi","year":"2009","journal-title":"Allergol Int"},{"key":"10.1016\/j.resinv.2025.101337_bib58","doi-asserted-by":"crossref","DOI":"10.1378\/chest.111.2_Supplement.11S","article-title":"One airway, one disease","volume":"111","author":"Grossman","year":"1997","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.101337_bib59","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11882-021-01013-y","article-title":"Biologic therapies for allergic rhinitis and nasal polyposis","volume":"21","author":"Geng","year":"2021","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.resinv.2025.101337_bib60","article-title":"Evaluating the efficacy of omalizumab in severe cedar seasonal allergic rhinitis in Japan","volume":"16","author":"Goto","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.resinv.2025.101337_bib61","doi-asserted-by":"crossref","first-page":"105S","DOI":"10.1378\/chest.124.4_MeetingAbstracts.105S-a","article-title":"Omalizumab, an Anti-IgE antibody, provides parallel improvements in symptoms of allergic asthma and perennial allergic rhinitis in patients with both diseases: the SOLAR stud","volume":"124","author":"Boulet","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.101337_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.anai.2014.05.011","article-title":"Clearance of Aspergillus fumigatus is impaired in the airway in allergic inflammation","volume":"113","author":"Fukahori","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib63","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.101337_bib64","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.3389\/fimmu.2018.02346","article-title":"Allergic bronchopulmonary Aspergillosis-A luminal hypereosinophilic disease with extracellular trap cell death","volume":"9","author":"Ueki","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib65","doi-asserted-by":"crossref","first-page":"212","DOI":"10.4103\/0970-2113.71949","article-title":"Occurrence of allergic bronchopulmonary mycosis in patients with asthma: an eastern India experience","volume":"27","author":"Sarkar","year":"2010","journal-title":"Lung India"},{"key":"10.1016\/j.resinv.2025.101337_bib66","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/ijmr.IJMR_1187_19","article-title":"Allergic bronchopulmonary aspergillosis","volume":"151","author":"Agarwal","year":"2020","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.resinv.2025.101337_bib67","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mai.2002.130179","article-title":"Allergic bronchopulmonary aspergillosis","volume":"110","author":"Greenberger","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.08-2586","article-title":"Allergic bronchopulmonary aspergillosis","volume":"135","author":"Agarwal","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.101337_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2016.11.019","article-title":"Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: a synthesis review of published literature","volume":"122","author":"Li","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.101337_bib70","doi-asserted-by":"crossref","first-page":"S110","DOI":"10.1093\/mmy\/myy063","article-title":"Challenging cases in fungal asthma","volume":"57","author":"Agarwal","year":"2019","journal-title":"Med Mycol"},{"key":"10.1016\/j.resinv.2025.101337_bib71","article-title":"Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis: a review of eight cases","volume":"12","author":"Tolebeyan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.resinv.2025.101337_bib72","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jaip.2020.03.023","article-title":"Mepolizumab for allergic bronchopulmonary aspergillosis: report of 20 cases from the Belgian severe asthma registry and review of the literature","volume":"8","author":"Schleich","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib73","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.jaip.2021.02.048","article-title":"Real-world effectiveness of Anti-IL-5\/5R therapy in severe atopic eosinophilic asthma with fungal sensitization","volume":"9","author":"Dhariwal","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejim.2021.12.026","article-title":"One-year mepolizumab for allergic bronchopulmonary aspergillosis: focus on steroid sparing effect and markers of response","volume":"99","author":"Caminati","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.resinv.2025.101337_bib75","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1038\/s41598-023-32246-8","article-title":"Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis","volume":"13","author":"Tomomatsu","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.resinv.2025.101337_bib76","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaip.2019.11.031","article-title":"Dupilumab treatment for allergic bronchopulmonary aspergillosis: a case series","volume":"8","author":"Ramonell","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib77","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.2169\/internalmedicine.6679-20","article-title":"Successful treatment of Mepolizumab- and prednisolone-resistant allergic bronchopulmonary aspergillosis with dupilumab","volume":"60","author":"Mikura","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2025.101337_bib78","article-title":"Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: a case report","volume":"39","author":"Kai","year":"2022","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.resinv.2025.101337_bib79","article-title":"A case of allergic bronchopulmonary aspergillosis with failure of benralizumab and response to dupilumab","volume":"15","author":"Kotetsu","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.resinv.2025.101337_bib80","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaip.2022.12.049","article-title":"Allergic bronchopulmonary aspergillosis in identical twins: effectiveness of dupilumab","volume":"11","author":"Lamothe","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.resinv.2025.101337_bib81","article-title":"Successful treatment with dupilumab in mepolizumab-resistant allergic bronchopulmonary aspergillosis","volume":"47","author":"Kawasaki","year":"2024","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.resinv.2025.101337_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1147","article-title":"Tezepelumab treatment for allergic bronchopulmonary aspergillosis","volume":"11","author":"Ogata","year":"2023","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.resinv.2025.101337_bib83","doi-asserted-by":"crossref","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5230","article-title":"Dupilumab improves lung function, asthma control and exacerbation frequency in allergic bronchopulmonary aspergillosis - results from the phase 2 LIBERTY ABPA AIRED study","volume":"211","author":"Bourdin","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101337_bib84","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.anai.2023.05.014","article-title":"Clinical impact of obesity on oscillometry lung mechanics in adults with asthma","volume":"131","author":"Chan","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107418","article-title":"Severity of adult-onset asthma - a matter of blood neutrophils and severe obesity","volume":"219","author":"Winsa-Lindmark","year":"2023","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2025.101337_bib86","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000314369","article-title":"Nationwide cross-sectional population-based study on the prevalences of asthma and asthma symptoms among Japanese adults","volume":"153","author":"Fukutomi","year":"2010","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib87","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000327555","article-title":"Association between body mass index and asthma among Japanese adults: risk within the normal weight range","volume":"157","author":"Fukutomi","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib88","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1398-9995.2012.02793.x","article-title":"The prevalence of rhinitis and its association with smoking and obesity in a nationwide survey of Japanese adults","volume":"67","author":"Konno","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.101337_bib89","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1164\/rccm.200611-1717OC","article-title":"Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies","volume":"175","author":"Beuther","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101337_bib90","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12325-018-0702-4","article-title":"Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab Efficacy\/Safety in patients with uncontrolled, moderate-to-severe asthma","volume":"35","author":"Busse","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.101337_bib91","article-title":"Dupilimab efficacy in patients with uncontrolled, moderate-to-severe asthma by body mass index","volume":"54","author":"Korn","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101337_bib92","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201208-1470OC","article-title":"Elevated sputum interleukin-5 and submucosal eosinophilia in Obese individuals with severe asthma","volume":"188","author":"Desai","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.101337_bib93","doi-asserted-by":"crossref","unstructured":"Da Cunha Fonseca A, Machado D, Pascoal I, Franco I, Lima R. Severe asthma in Obese patients: what to expect with mepolizumab? Eur Respir J;60:3216.","DOI":"10.1183\/13993003.congress-2022.3216"},{"key":"10.1016\/j.resinv.2025.101337_bib94","first-page":"A192","article-title":"P207 the influence of obesity on the clinical outcome of benralizumab treatment in severe eosinophilic asthma a subgroup analysis from the BPAP study","volume":"77","author":"Nanzer","year":"2022","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2025.101337_bib95","first-page":"A2490","volume":"197","author":"Trudo","year":"2018","journal-title":"Impact of body mass index on efficacy of benralizumab in patients with severe, uncontrolled eosinophilic asthma: pooled analysis of the SIROCCO and CALIMA trials"},{"key":"10.1016\/j.resinv.2025.101337_bib96","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12931-019-1134-7","article-title":"Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight\/body mass index: meta-analysis of MENSA and MUSCA","volume":"20","author":"Albers","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.101337_bib97","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pulmoe.2018.01.005","article-title":"Severe asthma in obese patients: improvement of lung function after treatment with omalizumab","volume":"25","author":"Oliveira","year":"2019","journal-title":"Pulmonology"},{"key":"10.1016\/j.resinv.2025.101337_bib98","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.anai.2022.01.025","article-title":"Impact of body mass index on omalizumab response in adults with moderate-to-severe allergic asthma","volume":"128","author":"Geng","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib99","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5578\/tt.20239904","article-title":"Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab","volume":"71","author":"Ediger","year":"2023","journal-title":"Tuberk Toraks"},{"key":"10.1016\/j.resinv.2025.101337_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.12.804","article-title":"Effect of tezepelumab on exacerbations in patients with severe, uncontrolled asthma, according to baseline body mass index: results from the phase 2b PATHWAY Study","volume":"145","author":"Ambrose","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.resinv.2025.101337_bib101","doi-asserted-by":"crossref","first-page":"A9","DOI":"10.1016\/j.chest.2023.07.075","article-title":"LONG-TERM efficacy of tezepelumab in patients with severe, Uncontrolled asthma by baseline body mass index","volume":"164","author":"Chupp","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.101337_bib102","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.101337_bib103","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","article-title":"DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2025.101337_bib104","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib105","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2024","article-title":"Type 2 airway inflammation in COPD","volume":"63","author":"Polverino","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101337_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12050708","article-title":"Asthma-COPD overlap syndrome: recent insights and unanswered questions","volume":"12","author":"Fouka","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.resinv.2025.101337_bib107","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101337_bib108","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1007\/s12325-020-01573-x","article-title":"Asthma and chronic obstructive pulmonary disease overlap according to the Japanese respiratory Society diagnostic criteria: the prospective, observational ACO Japan cohort Study","volume":"38","author":"Hashimoto","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.resinv.2025.101337_bib109","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136065","article-title":"Asthma and COPD overlap syndrome (ACOS): a systematic review and Meta analysis","volume":"10","author":"Alshabanat","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2025.101337_bib110","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1183\/09031936.06.00072105","article-title":"Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment","volume":"27","author":"Leigh","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2025.101337_bib111","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib112","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib113","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib114","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.101337_bib116","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2147\/COPD.S418944","article-title":"Benralizumab prevents recurrent exacerbations in patients with chronic obstructive pulmonary disease: a post hoc analysis","volume":"18","author":"Singh","year":"2023","journal-title":"Int J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.101337_bib117","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:19:18Z","timestamp":1768263558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525001923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2212534525001923"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.101337","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to choose a biologic agent considering comorbidities of bronchial asthma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.101337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}],"article-number":"101337"}}